Exagen gets conditional NY approval for new SLE/RA biomarkers; reports record 2024 revenue of $55.3-55.8M

EXAGEN INC.

2024-FY EPS reported -$0.83 revenue$55,641,000

Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.
Preliminary FY2024 revenue $55.3-$55.8M (record), net loss $14.8-$15.8M, adjusted EBITDA ($9.8)-($10.8M).
AVISE CTD trailing 12-mo ASP $408-$412, up $72-$76 vs Q4 2023; net neutral cash usage in Q4.
Cash, cash equivalents and restricted cash $22.2M as of Dec 31, 2024.
CEO says profitability 'firmly within reach' with strong growth catalysts entering 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.